Munich-based biotech firm smartbax has secured €6.3 million in a Pre-Series A financing round to advance its fight against antimicrobial resistance. The funding, completed with an investment from a Frankfurt-based family office, will accelerate its innovative antibiotic pipeline. This capital is earmarked to move the company's lead program through crucial preclinical development toward regulatory submission.
Strategic Funding to Combat Antimicrobial Resistance
The financing reached its €6.3 million total following a second closing led by a single family office from Frankfurt. This new backer joins a strong syndicate of investors, including Anobis Asset, Bayern Kapital, and the Boehringer Ingelheim Venture Fund. Such robust support underscores confidence in smartbax's pioneering approach to developing new antibiotics for critical infections.
These proceeds are instrumental for advancing smartbax's lead antibacterial program, recently in-licensed from Aicuris. The primary goal is guiding the candidate through preclinical development and preparing for an Investigational New Drug (IND) filing. Achieving this milestone will mark a significant maturation of the company's clinical pipeline and overall strategy.
Advancing a Novel Lead Antibiotic
The company's lead program features a novel small-molecule antibiotic targeting a previously unexploited pathway. It works by inhibiting the biosynthesis of lipopolysaccharides (LPS), an essential component of the outer membrane in Gram-negative bacteria. This specific targeting makes it a highly promising approach for developing a new class of treatments.
This therapeutic candidate has already achieved significant preclinical milestones, including demonstrating in vivo proof of concept. The program has shown potent activity against various multi-drug resistant pathogens, addressing a critical need in medicine. Furthermore, it has exhibited potential for oral bioavailability, offering a more convenient treatment option for patients.
Pioneering a Unique Mechanism of Action
In parallel, smartbax is advancing its proprietary pipeline of small-molecule antibiotics with a unique mechanism. This includes two activator programs designed to stimulate bacterial hydrolases, which are naturally occurring enzymes. This strategy effectively triggers a process of bacterial self-digestion, representing a fundamentally new therapeutic approach.
The company's proprietary programs target a broad spectrum of pathogens, including both Gram-positive and Gram-negative bacteria. These activators have shown promising drug-like properties and are effective at eradicating treatment-resistant biofilms. Crucially, no resistance development to this novel mechanism has been observed in preclinical studies to date.
Company Vision and Future Outlook
Dr. Robert Macsics, CEO of smartbax, noted that the funding provides resources to push the lead program toward an IND filing. He also emphasized the company's continued investment in its proprietary enzymatic activators, which offer a different approach to fighting infections. This dual strategy reinforces the company's mission to combat the growing threat of antimicrobial resistance.
Smartbax was established in 2021 as a spin-off from the Technical University Munich (TUM) to translate research into medical solutions. The company was founded on the principle that preventing a future resistance crisis requires immediate action. Its goal is to create novel antibiotics that provide significant value for patients facing serious infections worldwide.
The successful €6.3 million financing provides smartbax with the capital to accelerate its dual antibiotic development programs. This investment validates the company's innovative strategy, combining a novel LPS inhibitor with a unique self-digestion mechanism. With this support, smartbax is well-positioned to contribute significantly to the urgent global fight against multi-drug resistant bacteria.